

**REMARKS**

The Claims in the case are Claims 1, 2, 12, and 14-19. Claims 1, 2, and 12 have been allowed.

Claims 14-19 are rewritten versions of the process claims 3-11. Claims 14, 15 and 16 generally correspond to Claims 8, 10 and 11. Claims 17, 18, and 19 generally correspond to Claims 3, 10, and 11.

The Claims have been rewritten to avoid the rejection of the Claims under Section 112, both 1<sup>st</sup> and 2<sup>nd</sup> paragraphs. The claims particularly point out and distinctly claim the subject matter pertaining to the key step of the crystallization. Support for the amounts of the solvents is found in the specification at p. 5, lines 10-27, as well as the Examples.

Claims 5 and 7 have been cancelled, and the rejection of those claims is moot. The use of the term "e.g." is absent from the claims now present in the case. There is no improper dependency of newly added claims.

The abstract has been rewritten to provide a more complete statement.


Should the Office feel that telephonic communication with Applicants' representative would further the prosecution of the instant application, the examiner is invited to telephone the undersigned.

Early and favorable action on the merits is earnestly solicited.

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7903  
30950amend

Date: June 4, 2003

Respectfully submitted,



Hesna J. Pfeiffer  
Attorney for Applicants  
Reg. No. 22,640